Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Recruiting 37Completed 29Active not recruiting 22Terminated 7Withdrawn 3Not yet recruiting 3Unknown 2Available 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3CNS 1

Conditions

Breast Neoplasms 3HER2 Negative Breast Cancer Not Immediately Operated 1Brain Neoplasms 1

Interventions

Paclitaxel 28Trastuzumab 22Cyclophosphamide 21Doxorubicin 14Docetaxel 14Carboplatin 11exemestane 10Radiotherapy 10Letrozole 10Capecitabine 10pembrolizumab 8Lapatinib 8Fulvestrant 8Neoadjuvant Therapy 6Goserelin 6Bevacizumab 6Anastrozole 6pertuzumab 5palbociclib 5eribulin 5abemaciclib 5Therapeutics 5Magnetic Resonance Spectroscopy 5Epirubicin 5Chemotherapy, Adjuvant 5Aromatase Inhibitors 5tucatinib 4Vinorelbine 4Taxes 4Tamoxifen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Breast Neoplasms × ribociclib × Clear all
NCT06585969 2026-02-12

DISCORDANT

Danish Breast Cancer Cooperative Group

Phase 3 Withdrawn
Breast

Breast Neoplasms

NCT04585724 2021-10-18

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Emory University

Phase 1 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03081234 2018-03-15

EarLEE-2

Novartis

Phase 3 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡